# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> the loss of SIRT2 blunted the response of AMPK to metformin treatment in mice infused with Ang II and repressed the metformin-mediated reduction of cardiac hypertrophy and protection of cardiac function.

## Panel reviews

### `evidence_auditor` — `reject` (score 1)

The submission contains a critical failure in the citation trace for claim C022. The alias match for 'Loss' was resolved to 'AZASETRON', which is a completely unrelated pharmacological agent (a 5-HT3 receptor antagonist) and has no biological or chemical relationship to the 'loss of SIRT2' (a genetic knockout or protein deficiency) discussed in the thesis and claims. This represents a hallucinated or erroneous trace mapping.

**Flagged claims:** C022

### `domain_skeptic` — `reject` (score 3)

The submission suffers from severe mechanism inflation and a critical failure in entity resolution. Claim C022 attempts to generalize the findings from a specific mouse model (Ang II-infused) to 'aging-related' cardiac hypertrophy without providing evidence that the study actually addressed aging. This is a classic extrapolation error where a pathological stimulus (Ang II) is conflated with a biological process (aging).

Furthermore, the citation trace for C022 reveals a catastrophic alias error: 'Loss' (referring to the loss of SIRT2 protein/gene) was resolved to 'AZASETRON', a completely unrelated 5-HT3 receptor antagonist. This indicates that the evidence supporting the claim is either non-existent or fundamentally misinterpreted, rendering the mechanistic link between SIRT2, AMPK, and metformin invalid in the context of this submission.

**Flagged claims:** C022

### `final_judge` — `reject` (score 1)

I align with both the Evidence Auditor and the Domain Skeptic. The submission contains a catastrophic failure in the citation trace for C022, where the term 'Loss' (referring to the genetic deficiency of SIRT2) was erroneously resolved to 'AZASETRON', a 5-HT3 receptor antagonist. This is not a minor mapping error but a fundamental hallucination that invalidates the evidentiary chain for the claim. 

Additionally, I concur with the Domain Skeptic regarding the extrapolation of results from an Ang II-infused mouse model to 'aging-related' hypertrophy. There is no evidence provided that the cited study addressed aging, making the claim an unsupported generalization. Given that the core mechanistic link is supported by a corrupted trace and an overreached conclusion, the submission cannot be accepted.

**Flagged claims:** C022
